Compare Adobe Systems Inc (ADBE) vs ResMed Inc. (RMD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adobe Systems Inc vs ResMed Inc. — how do they compare? Adobe Systems Inc trades at $219.87 (market cap $88.06B), while ResMed Inc. trades at $209.03 (market cap $31.88B). The key difference: Adobe Systems Inc is far larger — about 2.8× ResMed Inc.'s market cap, and ResMed Inc. pays a 1.09% dividend while Adobe Systems Inc pays none. Which is the better fit depends on your goals.
| ADBE | RMD | |
|---|---|---|
Market Cap | $88.06B | $31.88B |
Volume | 5,187,646 | — |
Sector | Technology | Health |
52-Week High | $382.24 | $293.73 |
52-Week Low | $193.41 | $182.82 |
Enterprise Value | $89.50B | $31.06B |
Dividend Yield | — | 1.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adobe (ADBE) trades at $218.80, up 0.33% with a bullish technical signal despite recent volatility. The company demonstrates strong fundamentals with Q1 2026 EPS beating expectations at $5.96 versus $5.82, maintaining a trend of earnings outperformance. Revenue growth accelerated to $23.77B in 2025 with impressive net income margins of 28.69%. However, the stock faces headwinds from AI competition concerns and a recent CEO transition, contributing to a 31% YTD decline that has pushed shares near 52-week lows.
Adobe presents a compelling value opportunity trading at a P/E of 12.67x, significantly below historical averages, with analysts maintaining a $246.75 consensus target implying 13% upside. The primary risk remains competitive pressure from AI tools disrupting traditional software markets, though Adobe's strong cash flow generation and enterprise customer base provide defensive characteristics for long-term investors.
ResMed (RMD) trades at $219.75, up 4.83% on the day, with a bullish technical signal and strong earnings momentum after beating estimates for three consecutive quarters. The company reported robust fundamentals with 2025 revenue of $5.15B and net income of $1.40B, supported by a 27.44% net margin. Recent strategic moves include the sale of MatrixCare for $490M and the acquisition of Noctrix Health, sharpening focus on core sleep and respiratory care markets.
Outlook remains positive with a consensus price target of $267.33 implying 21.6% upside, though risks include competitive pressures and integration challenges from recent M&A. The stock's current valuation at 21.06 P/E appears reasonable given growth prospects, but investors should monitor execution on guidance and market share retention amid emerging threats like GLP-1 drugs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adobe Systems Inc
Adobe Inc. develops, markets, and supports computer software products and technologies. The Company's products allow users to express and use information across all print and electronic media. Adobe offers a line of application software products, type products, and content for creating, distributing, and managing information.
Read more on ADBE →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
